Advertisement

Reversal of Mivacurium: Neostigmine, Edrophonium, or Spontaneous Recovery — Which Makes More Sense?

  • A. F. Kopman
Conference paper

Abstract

The question, “is routine antagonism of neuromuscular block always necessary,” may never be settled to everyone’s satisfaction. Shortly after the introduction of atracurium and vecuronium into clinical practice Savarese suggested that “In many patients to whom these drugs have been given in proper dosage and with correct timing, reversal will not be required.”1 However, Miller states that “If one accepts the premise that even one case of severe, undetected respiratory depression and hypoxia in the PAW resulting in adverse effect is unacceptable, then .... complete reversal of neuromuscular blockade is the best prevention.”2 Prior to the availability of mivacurium, this latter position probably was most representative of clinical practice in North America. However, it is unclear that routine reversal of agents of mivacurium’s duration of action offers real benefits to the patient.

Keywords

Neuromuscular Blockade Neuromuscular Block Spontaneous Recovery Mivacurium Chloride Nondepolarizing Neuromuscular Block 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Savarese JJ: Newer Muscle Relaxants, in Thirty-eighth Annual Refresher Course Lectures and Clinical Update Program. American Society of Anesthesiologists, Inc., 1987, p 321Google Scholar
  2. 2.
    Miller RD: How should residual neuromuscular blockade be detected? Anesthesiology 70:379–380, 1989PubMedCrossRefGoogle Scholar
  3. 3.
    Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, We-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B 1090U): A short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology 68:723–732, 1988PubMedCrossRefGoogle Scholar
  4. 4.
    Goldhill DR, Whitehead JP, Emmott RS, Griffith AP, Bracey BJ, Flynn PJ: Neuromuscular and clinical effects of mivacurium chloride in healthy adult patients during nitrous oxide-enflurane anaesthesia. Br J Anaesth 67:289–295, 1991PubMedCrossRefGoogle Scholar
  5. 5.
    Caldwell JE, Heir T, Kitts JB, Lynam DP, Fahey MR, Miller RD: Comparison of the neuromuscular block induced by mivacurium, suxamethonium, or atracurium during nitrous oxide-fentanyl anaesthesia. Br J Anaesth 63:393–399, 1989PubMedCrossRefGoogle Scholar
  6. 6.
    Kopman AF: Unpublished data.Google Scholar
  7. 7.
    King ML, Milazkiewicz R, Carli F, Deacock AR: Influence of neostigmine on postoperative vomiting. Br J Anaesth 61:403–406, 1988PubMedCrossRefGoogle Scholar
  8. 8.
    Ding Y, Fredman B, White PF: Use of mivacurium during laparoscopic surgery: Effect of revers’ drugs on postoperative recovery. Anesth Analg 78:450–454, 1994PubMedCrossRefGoogle Scholar
  9. 9.
    Muravchick S, Owens WD, Felts JA: Glycopyrrolate and cardiac dysrhythmias in geriatric patients after reversal of neuromuscular blockade. Canad Anaesth Soc J 26:22–25, 1979PubMedCrossRefGoogle Scholar
  10. 10.
    Lawson JI: Cardiac arrest following the administration of neostigmine. Br. J. Anaesth 28:336–337, 1958CrossRefGoogle Scholar
  11. 11.
    Savarese JJ: Personal communication.Google Scholar
  12. 12.
    Bevan DR, Smith CE, Donati F: Neuromuscular blockade after surgery: Comparison of clinical assessment and evoked twitch responses. Anesthesiology 69:A475, 1988CrossRefGoogle Scholar
  13. 13.
    Bevan DR, Donati F, Kopman AF: Reversal of neuromuscular blockade. Anesthesiology 77:785–805, 1992PubMedCrossRefGoogle Scholar
  14. 14.
    Kopman AF: Tactile evaluation of train-of-four count as an indicator of reliability of antagonism from vecuronium or atracurium-induced neuromuscular blockade. Anesthesiology 75:588–593, 1991PubMedCrossRefGoogle Scholar
  15. 15.
    Salib, YM, Donati F, Bevan DR: Edrophonium antagonism of vecuronium at varying degrees of fourth twitch recovery. Can J Anaesth 40:839–843, 1993PubMedCrossRefGoogle Scholar
  16. 16.
    Cronnelly R, Morris RB, Miller RD: Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia .Anesthesiology 57:261–266, 1982Google Scholar
  17. 17.
    Cook DR, Chakravorti S, Brandom BW, Stiller RL: Effects of neostigmine, edrophonium and succinylcholine on the in vitro metabolism of mivacurium: clinical correlates. Anesthesiology 77:A948, 1992CrossRefGoogle Scholar
  18. 18.
    Kao YJ, Le N, Barker SJ: Neostigmine prolongs profound neuromuscular blockade induced by mivacurium in surgical patients. Anesthesiology 79:A929, 1993Google Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • A. F. Kopman
    • 1
  1. 1.Department of AnesthesiologySt. Vincent’s Hospital and Medical Center of New YorkNew YorkUSA

Personalised recommendations